Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Life's Grossman starts VC adventure; CEO takes stock

This article was originally published in Clinica

Executive Summary

Following the completion of its $13.6bn takeover by Thermo Fisher Scientific, former Life Technologies executive Paul Grossman has joined venture capital firm Telegraph Hill Partners as a venture partner. Dr Grossman was head of global strategy and corporate development at Life, where he was responsible for the company’s corporate strategy, licensing, business development and acquisition activities. Meanwhile, former Life chairman and CEO Greg Lucier is taking some time out after running a public company for 11 years, he told Clinica’s sister publication Scrip. Mr Lucier was appointed CEO of Invitrogen in 2003, which merged with Applied Biosystems in 2008 to form Life. He will remain active as a board member at companies including NuVasive, RainTree Oncology Services, Carefusion and the Sanford-Burnham Medical Institute in San Diego. "In time, I will get back into being a CEO," he said.

You may also be interested in...



Thermo Fisher Scientific Announces $11.5Bn Buyout Of Qiagen

Thermo Fisher expects the deal to improve its portfolio of specialty diagnostics for clinical labs while its genetic analysis technologies, biosciences reagents and consumable products will complement Qiagens’ sample preparation and assay technologies.

What are the hottest innovations from Israel?

Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.

EuroPCR: St Jude and Philips talk up rival intravascular imaging techs

St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.

Topics

UsernamePublicRestriction

Register

MT101330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel